LENZ Therapeutics, Inc.

LENZ Therapeutics is a U.S.-based pre-commercial biopharmaceutical company focused on developing and commercializing VIZZ, an aceclidine-based eye drop for presbyopia. The company’s business model is currently centered on launching VIZZ in the United States and expanding rights through licensing deals in selected international markets.

−476,0 %

97,8 %

−430,3 %

14.23

14.09

— LENZ Therapeutics, Inc.
%
Commercial ophthalmic product70% VIZZ is the company’s FDA-approved aceclidine-based treatment for presbyopia in the U.S.
International licensing30% Exclusive regional licenses for LNZ100 generate upfront, milestone and royalty revenue.
Commercialization services0% Sales, marketing and launch activities supporting adoption by eye care professionals and pharmacies.

LENZ sells primarily to eye care professionals and, through pharmacy channels, to patients seeking treatment for...

  • Eye care professionalsprimary

    Optometrists and ophthalmologists who evaluate presbyopia patients and decide whether to prescribe VIZZ.

  • Presbyopia patientsprimary

    Adults seeking a prescription treatment for age-related near-vision loss and convenience versus glasses or alternatives.

  • Pharmacy distribution channelssecondary

    Retail and e-pharmacy partners that fulfill prescriptions and broaden access after launch.

  • International pharmaceutical licenseessecondary

    Partners such as Lotus and Théa that pay for rights to commercialize LNZ100 in specific regions.

LENZ is commercially focused on the United States, where VIZZ was approved and launched in 2025...

  • •United States is the core launch market for VIZZ
  • •Southeast Asia is licensed to Lotus Pharmaceutical
  • •Canada is licensed to Laboratoires Théa
  • •Greater China is a regulatory and partnering focus for LNZ100
  • •International expansion is asset-light and partner-led

LENZ’s strategy is to convert VIZZ’s FDA approval into commercial uptake in the U.S. while using targeted partnerships...

01
U.S. commercialization of VIZZshort-term

Near-term value creation depends on converting FDA approval into prescriptions and pharmacy availability.

02
Brand and market awarenessshort-term

Presbyopia treatment adoption depends on ECP and patient familiarity with a new branded therapy.

03
International partneringmedium-term

Licensing reduces capital intensity and creates non-dilutive revenue from milestones and royalties.

04
IP and exclusivity protectionmedium-term

Patent and NCE exclusivity are central to defending pricing power and blocking copycat competition.

LENZ is highly dependent on a single product, VIZZ, so any launch misstep, safety issue or weak market acceptance could...

critical

Dependence on VIZZ as the only commercial product

The company states its business depends entirely on VIZZ and has no additional product candidates in the current pipeline.

Scope
Commercial revenue, valuation and operating leverage
Materiality
high
high

Weak market acceptance by eye care professionals and patients

Presbyopia treatment adoption requires brand awareness and physician/patient willingness to switch from existing options.

Scope
Prescription volume and launch trajectory
Materiality
high
high

Third-party manufacturing and supply chain disruption

LENZ relies on external manufacturers for product supply and clinical/commercial quantities.

Scope
Product availability, launch timing and gross margin
Materiality
high
high

Competition from branded, generic and off-label products

Competitors may offer safer, more effective or cheaper alternatives, including generic versions.

Scope
Pricing, market share and physician preference
Materiality
high
medium

Regulatory and clinical execution risk

Future approvals, post-marketing commitments and foreign registrations depend on successful regulatory execution.

Scope
International expansion and label maintenance
Materiality
medium
License and collaboration revenue recognition
Can cause lumpy revenue from Lotus, Théa and CORXEL agreements
Stock-based compensation valuation
Can materially affect operating expenses and loss trends
R&D accrual estimates
May shift expenses between periods if estimates change
Third-party manufacturing and contract commitments
Affects accrued liabilities and cash burn visibility

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

CELZ · Biological Products, (No Diagnostic Substances)

TENAX THERAPEUTICS, INC.

TENX · Pharmaceutical Preparations

IONIS PHARMACEUTICALS INC

IONS · Pharmaceutical Preparations

Lexeo Therapeutics, Inc.

LXEO · Biological Products, (No Diagnostic Substances)

LB PHARMACEUTICALS INC

LBRX · Pharmaceutical Preparations

Inhibitor Therapeutics, Inc.

INTI · Pharmaceutical Preparations

: 28.4.2026